ArticleFrontiers in genetics2022

Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China.

Haonan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.